Arecor due to transfer formulation for new medicine to Hikma Pharmaceuticals in first half of 2022

Arecor Therapeutics expects to transfer the final formulation for a new ready-to-use, injectable medicine to Hikma Pharmaceuticals in the first half of 2022.

The Chesterford Research Park company announced a co-development agreement for AT282 - in an undisclosed indication - with the London-based pharma company in January 2020, which led to an upfront payment.

Arecor is responsible for optimising the formulation using its proprietary Arestat technology platform. A milestone payment will be triggered when Arecor hands over the formulation.

Sarah Howell, CEO of Arecor, said: "We are pleased with the progress being made with AT282, the first of two co-development programmes with Hikma. Ready-to-use medicines such as AT282 are becoming increasingly important in the hospital setting and we are proud that our ArestatTM technology is supporting the development of a medicine that has the potential to provide a safer, more convenient and immediate treatment option for patients. We look forward to updating the market on our continued progress with this programme.”

Read more

Enter the Cambridge Independent Science and Technology Awards 2021-22

Arecor Therapeutics to develop intravenous formulation of Par Sterile Products’ medicine